Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modern prostate brachytherapy.

H Ragde1, G L Grado, B Nadir

  • 1Prostate Brachytherapy at Southwest Oncology Center, Scottsdale, AZ, USA.

CA: a Cancer Journal for Clinicians
|January 9, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone.

Archivos espanoles de urologia·2001
Same author

Selective activation of the fatty acid synthesis pathway in human prostate cancer.

International journal of cancer·2000
Same author

Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up.

Cancer·2000
Same author

Techniques to achieve optimal seed placement in salvage and primary brachytherapy for prostate cancer.

Techniques in urology·2000
Same author

Follow-up ProstaScint scans verify detection of occult soft-tissue recurrence after failure of primary prostate cancer therapy.

The Prostate·2000
Same author

Prostate-specific membrane antigen (PSMA): current benefits and future value.

Seminars in surgical oncology·2000

Prostate brachytherapy, the permanent implantation of radioactive seeds, is a minimally disruptive treatment for organ-confined prostate cancer. Long-term data show 66% disease-free survival with monotherapy and 79% with combined therapy for higher-grade disease.

Area of Science:

  • Oncology
  • Radiation Oncology
  • Urology

Background:

  • Prostate brachytherapy is the oldest radiation technique for prostate cancer, predating external beam therapy.
  • It offers a minimally disruptive treatment option for organ-confined prostate cancer compared to other modalities.
  • Treatment decisions often rely on patient/physician preference and clinical data due to a lack of definitive comparative studies.

Discussion:

  • Long-term outcomes demonstrate significant disease-free survival rates for prostate brachytherapy.
  • Monotherapy with seed implants achieved 66% disease-free survival.
  • A combination of brachytherapy and external beam radiation yielded 79% disease-free survival in higher-grade cases.

Key Insights:

  • Brachytherapy provides a favorable long-term disease-free survival for organ-confined prostate cancer.

Related Experiment Videos

  • Combined brachytherapy and external beam radiation are effective for higher-grade prostate cancer.
  • Patient selection and technique are crucial for optimal outcomes.

    • Outlook:

    • Continued evaluation of long-term outcomes will refine treatment protocols.
    • Further research may explore optimal combinations of brachytherapy and other treatment modalities.
    • Advancements in implant techniques aim to improve precision and efficacy.